Morphic is a biopharmaceutical company. Co. is engaged in discovering and developing a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Co. is advancing its preclinical pipeline, including its wholly-owned program MORF-057, an a4ß7 integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease. Co. is also developing MORF-720, its selective oral avß6 integrin inhibitor affecting fibrosis. The MORF stock yearly return is shown above.
The yearly return on the MORF stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MORF annual return calculation with any dividends reinvested as applicable (on ex-dates).
|